Trial · NCT01943851
Participant flow108
How many started, completed or left each group, period by period.
21 to 40 of 108
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 20 mg QD | 1 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 30 mg QD MM | 4 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 40 mg QD | 0 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 40 mg QD MM | 4 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 60 mg QD AML | 7 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 60 mg QD NHL | 16 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 60 mg QD MM | 2 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 75 mg QD AML | 8 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 80 mg QD | 1 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 80 mg QD AML | 7 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 80 mg QD NHL | 7 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 100 mg QD AML | 15 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 1: GSK525762 120 mg QD AML | 6 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 2: GSK525762 60 mg QD CTCL | 0 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 2: GSK525762 75 mg QD MDS | 0 | |
| Part 1 (Up to 86.9 Weeks) | COMPLETED | Part 2: GSK525762 80 mg QD CTCL | 0 | |
| Part 1 (Up to 86.9 Weeks) | NOT COMPLETED | Part 1: GSK525762 5 mg QD | 0 | |
| Part 1 (Up to 86.9 Weeks) | NOT COMPLETED | Part 1: GSK525762 10 mg QD | 0 | |
| Part 1 (Up to 86.9 Weeks) | NOT COMPLETED | Part 1: GSK525762 20 mg QD | 0 | |
| Part 1 (Up to 86.9 Weeks) | NOT COMPLETED | Part 1: GSK525762 30 mg QD MM | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01943851/flow?page=2